社区老年人嗅觉与阿尔茨海默病及神经退行性血浆生物标志物的关联
本研究基于ARIC队列1545名社区老年人(平均76岁,60%女性,27%自报黑人),横断面分析发现嗅觉识别能力越差,血浆p-tau181、p-tau181/Aβ42、GFAP和NfL水平越高,Aβ42/Aβ40比值越低;嗅觉完全丧失与多种神经病理标志物相关,内侧颞叶体积缩小部分解释了这些关联。
要点
- 嗅觉减退与AD相关血浆生物标志物升高相关,提示其可作为早期风险信号。
- 嗅觉完全丧失者血浆p-tau181/Aβ42和NfL显著升高,但Aβ42/Aβ40比值关联不显著。
- 内侧颞叶体积缩小部分介导嗅觉与神经退行标志物的关联。
核心结论
- 嗅觉差与多种AD相关及其他神经退行性过程相关,支持嗅觉作为神经退行性变的早期标志。
研究设计与样本
- 横断面研究,纳入ARIC研究第5次随访(2011-2013)的1545名社区老年人,完成嗅觉测试、脑MRI和血浆生物标志物检测。
主要发现
- 嗅觉评分每降低1分,血浆p-tau181升高β=0.026(95%CI 0.012-0.040),p-tau181/Aβ42升高β=0.027(95%CI 0.011-0.044),GFAP升高β=0.024(95%CI 0.009-0.040),NfL升高β=0.034(95%CI 0.019-0.050),Aβ42/Aβ40降低β=-0.007(95%CI -0.015至0.000)。
- 与嗅觉正常者相比,嗅觉完全丧失者血浆p-tau181/Aβ42升高β=0.235(95%CI 0.113-0.358),NfL升高β=0.210(95%CI 0.102-0.317),但Aβ42/Aβ40比值差异无统计学意义(β=-0.054,95%CI -0.108至0.001)。
- 嗅觉减退和中等正常嗅觉与上述生物标志物无显著关联。
- 内侧颞叶体积缩小部分解释了嗅觉与p-tau181、p-tau181/Aβ42、GFAP和NfL的关联。
临床怎么用
- 在社区老年人中,嗅觉测试异常(尤其嗅觉完全丧失)可提示进一步评估血浆AD及神经退行生物标志物。
- 嗅觉减退但未完全丧失者,生物标志物关联不显著,需结合其他临床信息综合判断。
局限性
- 横断面设计无法推断因果关系,需纵向研究探讨嗅觉与生物标志物的动态关系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Investigation of olfactory impairment, an early manifestation of Alzheimer disease (AD), in relation to plasma biomarkers of AD and neurodegeneration could provide insights into the disease's pathophysiology. Because few such studies based on large, diverse, community-based populations exist, we investigated associations of odor identification ability with plasma biomarkers of AD and other neurodegenerative pathologies in community-dwelling Black and White older adults. METHODS: This cross-sectional investigation included participants from the Atherosclerosis Risk in Communities study who attended visit 5 (2011-2013) and who completed olfactory testing and brain MRI examinations and had plasma biomarkers measured (namely, amyloid-beta [Aβ]42/Aβ40 ratio, phosphorylated-tau at threonine-181 [p-tau181], p-tau181/Aβ42 ratio, glial fibrillary acidic protein [GFAP], and neurofilament light chain [NfL]). Odor identification ability was measured by the 12-item Sniffin' Sticks test. Separate linear regression models were used to examine the association of continuous olfaction score and olfaction categories (anosmia: score 6; hyposmia: 7-8; moderate-normal: 9-10; good-normal: 11-12) with each biomarker (all were log-transformed), adjusting for sociodemographic and cardiovascular factors, head injury, APOE-ε4 status, and estimated glomerular filtration rate. We further examined whether any observed associations are explained by total and regional brain volumes. RESULTS: Among 1,545 participants (age: 76 ± 5 years, 60% women, 27% self-reported Black participants), the mean olfaction score was 9.2 ± 2.3; 14% had anosmia. Consistent with our hypotheses, poorer olfactory scores were associated with higher plasma p-tau181 (β per 1-unit lower score: 0.026 [95% CI 0.012-0.040]), p-tau181/Aβ42 (β: 0.027 [95% CI 0.011- 0.044]), GFAP (β: 0.024 [95% CI 0.009-0.040]), and NfL (β: 0.034 [95% CI 0.019-0.050] and lower Aβ42/Aβ40 ratio (β: -0.007 [95% CI -0.015 to 0.000]). Likewise, compared with good-normal olfaction, anosmia showed associations with all biomarker levels indicative of greater neuropathology (e.g., β for plasma p-tau181/Aβ42: 0.235 [95% CI 0.113-0.358] and β for plasma NfL: 0.210 [95% CI 0.102-0.317]), although the association with Aβ42/Aβ40 ratio was not statistically significant (β: -0.054 [95% CI -0.108 to 0.001]). These biomarkers were not significantly associated with hyposmia or moderate-normal olfaction. Smaller medial-temporal lobe volumes partly explained olfaction's link with plasma p-tau181, p-tau181/Aβ42, GFAP, and NfL. DISCUSSION: Our findings suggest that poor olfaction is associated with multiple AD-related and other neurodegenerative processes. Future studies should investigate how longitudinal changes in both olfaction and biomarkers relate to each other.
引用
- Shrestha S, Zhu X, Griswold ME, et al. Olfaction and Plasma Biomarkers of Alzheimer Disease and Neurodegeneration in the Atherosclerosis Risk in Communities Study. Neurology. 2025. PMID: 40373252. doi:10.1212/WNL.0000000000213706
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。